Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
[18F]MNI-1054 Biodistribution and Safety in Healthy Subjects
NCT03719482Phase 1Completed
- Sponsor
- Invicro
- Start
- Oct 2018
- Primary completion
- May 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of [18F]MNI-1054 in Alzheimer's disease (AD), sponsored by Invicro. Primary endpoints: Assessment of body organ distribution at 2 months and Radiation dosimetry of [18F]MNI-1054 at 2 months. Started Oct 2018; status: completed.
02
Drugs
[18F]MNI-1054
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT03719482.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03719482.